Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim

Summary

Guggenheim analyst notes that Akeso's positive Phase 3 lung cancer trial data lends credibility to Summit's global lung cancer trial program. The analyst commentary suggests increased confidence in Summit's clinical development pipeline.